![Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEE A]-OH](https://images.cnmqh.com/images/a10134/5a61d17a9106f75aeeeb68ee1fdd5a19-20260119055956.webp "Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEE A]-OH")
![Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEE A]-OH](https://images.cnmqh.com/images/a10134/ims-8-20260114010926.webp "Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEE A]-OH")
![Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEE A]-OH](https://images.cnmqh.com/images/a10134/ims-4-20260114004518.webp "Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEE A]-OH")
![Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEE A]-OH](https://images.cnmqh.com/images/a10134/4627290c2bfaa37a34200bcf273b9d3b-20260113060434.webp "Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEE A]-OH")
Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEE A]-OH
Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEE A]-OH
TECHNICAL SPECIFICATIONS
| Item | Specification |
|---|---|
| Product Name | Fmoc - L - Lys[C₂₀ - OtBu - Glu(OtBu) - AEEA - AEEA] - OH |
| CAS NO. | \ |
| Appearance | White to off-white lyophilized powder |
| Molecular Formula | \ |
| Molecular Weight | \ |
| Amino Acid Sequence | C₂₀ - OtBu - Glu(OtBu) - AEEA - AEEA |
| Purity (RP-HPLC) | ≥ 98.0% |
| Solubility | Soluble in common peptide - soluble solvents such as dimethylformamide (DMF), dimethyl sulfoxide (DMSO) |
| Endotoxin | < 1.0 EU/mg |
| Biological Activity | As a modified lysine - containing peptide, it may be involved in various biological processes related to lysine - dependent functions. Specific activity depends on the intended application, such as in peptide - based drug discovery, biomaterials research or protein - peptide interaction studies. |
| Storage Conditions | Store at - 20°C in a dry, inert gas (such as nitrogen) - filled environment. Protect from light and moisture. Avoid repeated freeze - thaw cycles. |
| Stock Location | Stock in USA |
| MOQ | 1g |
1.MECHANISM OF ACTION
Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEEA]-OH is a long-chain fatty acid-modified lysine derivative designed for lipidated peptide synthesis in drug discovery and bioconjugate development. The Fmoc (9-fluorenylmethyloxycarbonyl) group protects the α-amino group, enabling selective deprotection during solid-phase peptide synthesis (SPPS). The ε-amino group of lysine is extended with a C20 fatty acid chain terminated with a tert-butyl ester (OtBu) protecting group, followed by a glutamic acid (Glu) unit also protected with OtBu, and two AEEA (8-amino-3,6-dioxaoctanoic acid) linkers.
This structure allows the attachment of a long hydrophobic tail to peptides, enhancing membrane permeability, serum stability, and targeting properties in biological systems. During synthesis, the Fmoc group is removed under mild basic conditions (piperidine), exposing the α-amino group for sequential coupling. The OtBu esters remain intact until final acidic global deprotection (commonly with TFA), releasing the free carboxylic acids for conjugation or further modifications. This modular protection strategy ensures precise control over peptide sequence and lipidation pattern.
2.PRODUCT INDICATIONS
Primary Synthetic Target:
Used as a building block for lipidated peptide synthesis, especially for GLP-1 analogs, long-acting peptide drugs, and conjugated peptide therapeutics.
Peptide Drug Applications:
Incorporation into peptides requiring prolonged half-life and improved bioavailability via albumin binding or fatty acid-mediated stabilization.
Ideal for developing once-weekly injectable peptide formulations.
Research & Development Uses:
Preclinical studies on structure-activity relationships (SAR) of lipidated peptides.
Synthesis of peptide-drug conjugates (PDCs) and targeted peptide therapeutics.
Industrial Applications:
Manufacturing of biopharmaceutical peptides with enhanced pharmacokinetics for metabolic diseases, oncology, and rare diseases.
3.CLINICAL EFFICACY OF PRODUCT
| Item | Specification |
|---|---|
| Product Name | Fmoc - L - Lys[C₂₀ - OtBu - Glu(OtBu) - AEEA - AEEA] - OH |
| CAS NO. | \ |
| Appearance | White to off-white lyophilized powder |
| Molecular Formula | \ |
| Molecular Weight | \ |
| Amino Acid Sequence | C₂₀ - OtBu - Glu(OtBu) - AEEA - AEEA |
| Purity (RP-HPLC) | ≥ 98.0% |
| Solubility | Soluble in common peptide - soluble solvents such as dimethylformamide (DMF), dimethyl sulfoxide (DMSO) |
| Endotoxin | < 1.0 EU/mg |
| Biological Activity | As a modified lysine - containing peptide, it may be involved in various biological processes related to lysine - dependent functions. Specific activity depends on the intended application, such as in peptide - based drug discovery, biomaterials research or protein - peptide interaction studies. |
| Storage Conditions | Store at - 20°C in a dry, inert gas (such as nitrogen) - filled environment. Protect from light and moisture. Avoid repeated freeze - thaw cycles. |
| Stock Location | Stock in USA |
| MOQ | 1g |
1.MECHANISM OF ACTION
Fmoc-L-Lys[C20-OtBu-Glu(OtBu)-AEEA-AEEA]-OH is a long-chain fatty acid-modified lysine derivative designed for lipidated peptide synthesis in drug discovery and bioconjugate development. The Fmoc (9-fluorenylmethyloxycarbonyl) group protects the α-amino group, enabling selective deprotection during solid-phase peptide synthesis (SPPS). The ε-amino group of lysine is extended with a C20 fatty acid chain terminated with a tert-butyl ester (OtBu) protecting group, followed by a glutamic acid (Glu) unit also protected with OtBu, and two AEEA (8-amino-3,6-dioxaoctanoic acid) linkers.
This structure allows the attachment of a long hydrophobic tail to peptides, enhancing membrane permeability, serum stability, and targeting properties in biological systems. During synthesis, the Fmoc group is removed under mild basic conditions (piperidine), exposing the α-amino group for sequential coupling. The OtBu esters remain intact until final acidic global deprotection (commonly with TFA), releasing the free carboxylic acids for conjugation or further modifications. This modular protection strategy ensures precise control over peptide sequence and lipidation pattern.
2.PRODUCT INDICATIONS
Primary Synthetic Target:
Used as a building block for lipidated peptide synthesis, especially for GLP-1 analogs, long-acting peptide drugs, and conjugated peptide therapeutics.
Peptide Drug Applications:
Incorporation into peptides requiring prolonged half-life and improved bioavailability via albumin binding or fatty acid-mediated stabilization.
Ideal for developing once-weekly injectable peptide formulations.
Research & Development Uses:
Preclinical studies on structure-activity relationships (SAR) of lipidated peptides.
Synthesis of peptide-drug conjugates (PDCs) and targeted peptide therapeutics.
Industrial Applications:
Manufacturing of biopharmaceutical peptides with enhanced pharmacokinetics for metabolic diseases, oncology, and rare diseases.
3.CLINICAL EFFICACY OF PRODUCT
Synthesis Efficiency:
High coupling yields (>95%) achieved in SPPS protocols using this lipidated lysine derivative, minimizing deletion and truncation byproducts.
Purity & Quality:
RP-HPLC purity typically ≥95%, ensuring reliable downstream peptide quality.
Residual protecting-group levels below pharmacopoeial limits after global deprotection.
Stability:
Stable under recommended storage (−20 °C, dry, inert atmosphere); shelf life exceeds 24 months when sealed properly.
Scalability:
Successfully scaled from milligram to multi-gram batches for preclinical peptide candidate production.
Safety Profile:
Non-toxic under standard laboratory handling; follow standard PPE protocols due to organic solvent use during synthesis.
4.DELIVERY & SHIPPING
We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight
We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.
Nov 05, 26
Global Market Analysis and Oxandrolone 50mg Price Guide
For B2B pharmaceutical buyers and researchers, understanding the oxandrolone 50mg price involves analyzing more than just a numerical value; it requires a comprehensive look at API purity, synthesis methods, and global supply chain stability. As a specialized anabolic steroid derivative, the cost is heavily influenced by the quality of raw materials and the rigor of the laboratory testing involved in the production process. This article explores the economic and technical variables that dictate market pricing for this specific compound. In the context of the global API market, pricing volatility is often tied to regulatory shifts in key manufacturing hubs
Nov 04, 26
How to Select High Purity Alisol C CAS 30489271 for Laboratory Research
High Purity Alisol C CAS 30489271 is suited to laboratories using Alisol C as a triterpenoid reference standard in metabolic, hepatology, pharmacology, HPLC/MS, botanical-extract, or selected cell-line research. We explain the application fit and the identity, purity, physical form, solvent, endotoxin, storage, quantity, and batch-record checks to make before ordering.
Nov 02, 26
Reliable Oxandrolone Supplier for High Purity Pharmaceutical APIs
When sourcing high-purity pharmaceutical ingredients for endocrine or cardiovascular research, the reliability of the supply chain is as critical as the chemical purity itself. For laboratories and manufacturers seeking a dependable oxandrolone supplier, the focus must extend beyond simple certificates of analysis to encompass consistent batch-to-batch stability and strict adherence to GMP standards. Whether the requirement is for small-scale pilot studies or large-scale industrial production, the ability to trace materials from raw synthesis to final lyophilized powder ensures the integrity of the resulting clinical or research data.